DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Australia
  • /
  • Healthcare
Published
01 Feb 26
Views
30
Not Invested
ImExHSIME
IME logo
Fair Value
AU$1.04
Share price01 Feb
AU$0.2873.1% undervalued intrinsic discount
Loading
1Y5.66%
7D-13.85%

Plenty of upside

WO
Wobbegong

Author hasn't set their bio yet

Published
01 Feb 26
Views
30
Not Invested
Fair ValueAU$1.04
Share priceAU$0.28
73.1% undervalued intrinsic discount
Narrative
Updates0

The quarterly release indiates the company is getting through to profitability and cashflow sustainability. Management team seems to have done a good job across the board – cash, price, volume, renegotiations, cost control, efficiency, etc. They also understand the challenge now is to drive the software sales and revenue much faster in 2026. Despite the relatively small software development spend (circa AUD800K) they seem to be getting a very good bang for the buck with a lot of new releases in the quarter. The radiology business has achieved a solid return to positive contribution in the second half.

Have other thoughts on ImExHS?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

The user Wobbegong holds no position in ASX:IME. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

IME logo
ImExHS
24.3% undervalued intrinsic discount

Cloud Adoption And AI Integration Will Support A Stronger Long Term Outcome

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Sep
Read Narrative

Fair Value vs Share Price

AU$1.04
vs AU$0.2873.1% undervalued intrinsic discount
PastFuture-6m26m20152018202120242026202720302031Revenue AU$18.9mEarnings AU$2.6m
-6.4%
Revenue growth
13.8%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on ImExHS

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Excellent balance sheet with reasonable growth potential.

Market capAU$15.2m
PB0.9x
Estimated Growth8.8%
Dividend YieldN/A
Full analysis

CEO & management

German Arango
CEO
0.2yrs
CEO Tenure

Offers cloud-based medical imaging solutions in Australia and internationally.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide